10.70
전일 마감가:
$10.45
열려 있는:
$10.595
하루 거래량:
289.79K
Relative Volume:
0.37
시가총액:
$736.28M
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-5.8791
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
+6.36%
1개월 성능:
+29.23%
6개월 성능:
+21.32%
1년 성능:
+11.87%
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
명칭
Eyepoint Pharmaceuticals Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
EYPT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
EYPT
Eyepoint Pharmaceuticals Inc
|
10.70 | 719.08M | 46.02M | -70.80M | -1.61M | -1.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
2025-01-07 | 개시 | Citigroup | Buy |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-08-28 | 개시 | Jefferies | Buy |
2024-01-22 | 개시 | JP Morgan | Overweight |
2023-11-02 | 개시 | Mizuho | Buy |
2023-04-21 | 개시 | Robert W. Baird | Outperform |
2022-07-07 | 개시 | Chardan Capital Markets | Buy |
2021-03-01 | 개시 | Cowen | Outperform |
2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
2019-11-04 | 재개 | Laidlaw | Buy |
2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
Is EyePoint Pharmaceuticals Inc. a good long term investmentExceptional earning trajectories - jammulinksnews.com
What drives EyePoint Pharmaceuticals Inc. stock priceGame-changing returns - jammulinksnews.com
What analysts say about EyePoint Pharmaceuticals Inc. stockTremendous return on equity - jammulinksnews.com
EyePoint Pharmaceuticals Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 563 - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards 63,900 Shares in Employee Stock Options Under NASDAQ Rule - Stock Titan
EyePoint Pharmaceuticals Acquisition by Federated Hermes Highlights Interest in Healthcare Sector - AInvest
What makes EyePoint Pharmaceuticals Inc. stock price move sharplyFree Insider Trading Tips - beatles.ru
Pleasing Signs As A Number Of Insiders Buy EyePoint Pharmaceuticals Stock - simplywall.st
EyePoint Pharmaceuticals (EYPT) Soars 10.15% on Clinical Trial Progress - AInvest
Trend Tracker for (EYPT) - news.stocktradersdaily.com
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) dropped from Russell 3000E Growth Index - MarketScreener
EyePoint Pharmaceuticals Approves Share Increase at Annual Meeting - TipRanks
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals - Benzinga
RBC Capital Initiates Coverage on EyePoint Pharmaceuticals (EYPT - GuruFocus
EyePoint Pharmaceuticals (EYPT) Poised for Success with Positive Outlook | EYPT Stock News - GuruFocus
RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target - MarketScreener
After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
EyePoint (EYPT) Grants Stock Options to New Employees as Inducement | EYPT Stock News - GuruFocus
EyePoint Awards 12,500 Shares in Stock Options to Three New Hires at $9.03 Per Share - Stock Titan
(EYPT) Trading Report - news.stocktradersdaily.com
EyePoint Stock: Retaining My 'Risky Buy' CallPivotal Data Due Early 2026 (NASDAQ:EYPT) - Seeking Alpha
Cantor Fitzgerald Weighs in on EYPT FY2026 Earnings - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint at Goldman Sachs Healthcare Conference: Sustained-Release Vision By Investing.com - Investing.com Canada
Breakout Momentum Plays You May Not Know About - Investing.com
Squarepoint Ops LLC Has $302,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Ameriprise Financial Inc. Grows Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Nuveen Asset Management LLC Raises Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Cookies Notice - EyePoint Pharmaceuticals
ProShare Advisors LLC Buys 8,981 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
(EYPT) Investment Report - news.stocktradersdaily.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $276,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
Millennium Management LLC Buys New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint advances with Duravyu Phase III trial - Yahoo
Eyepoint Pharmaceuticals Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):